Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis

Journal of Antibiotics

Volumn 68, Issue 11, 2015, Pages 711-714

  Piccaro, Giovanni ^a   Poce, Giovanna ^b   Biava, Mariangela ^b   Giannoni, Federico ^a   Fattorini, Lanfranco ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLAVULANIC ACID; CLOFAZIMINE; DRUG; LINEZOLID; MEROPENEM; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; POSIZOLID; PRETOMANID; RIFAPENTINE; THIORIDAZINE; TUBERCULOSTATIC AGENT;

ARTICLE; COLONY FORMING UNIT; DRUG MECHANISM; DRUG PENETRATION; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUBERCULOSIS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTITUBERCULAR AGENTS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84948651608     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2015.52     Document Type: Article

References (25)

1. Zumla, A.I.et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis. 14, 327-340 (2014
2. Poce, G., Cocozza, M., Consalvi, S. & Biava, M. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. Eur. J. Med. Chem. 86, 335-351 (2014
3. Kim, M. J, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol. Med. 2, 258-274 (2010
4. Wayne, L. G. & Hayes, L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64, 2062-2069 (1996
5. Piccaro, G., Giannoni, F., Filippini, P., Mustazzolu, A. & Fattorini, L. Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions. Antimicrob. Agents Chemother. 57, 1428-1433 (2013
6. Poce, G, et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One. 8, e56980 (2013
7. Hillemann, D., Rüsch-Gerdes, S. & Richter, E. In vitro-selected linezolidresistant Mycobacterium tuberculosis mutants. Antimicrob. Agents Chemother. 52, 800-801 (2008
8. Coban, A. Y., Bilgin, K., Tasdelen Fisgin, N., Uzun, M. & Durupinar, B. Effect of meropenem against multidrug-resistant Mycobacterium tuberculosis. J. Chemother. 20, 395-396 (2008
9. Ekins, S., Freundlich, J. S., Choi, I., Sarker, M. & Talcott, C. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. Trends Microbiol. 19, 65-74 (2011
10. Goldman, R. C. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?. Tuberculosis. 93, 569-588 (2013
11. Dashti, Y., Grkovic, T. & Quinn, R. J. Predicting natural product value, an exploration of anti-TB drug space. Nat. Prod. Rep. 31, 990-998 (2014
12. Makarov, V, et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol. Med. 6, 372-383 (2014
13. Takacs-Novak, K. in Physico-Chemical Methods in Drug Discovery and Development (ed. Mandic E.) 2-52 International Association of Physical Chemists (IAPC) Publishing, Zagreb, Croatia, (2012
14. Gillespie, S. H, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577-1587 (2014
15. Merle, C. S, et al A four-month gatifloxacin-containing regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588-1598 (2014
16. Jindani, A, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371, 1599-1608 (2014
17. World Health Organization. Global Tuberculosis Report 2014. Chapter 9: Research and development. WHO/HTM/TB/2014.08.
18. Williams, K, et al. Sterilizing activities of novel combinations lacking first- and secondline drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56, 3114-3120 (2012
19. Tasneen, R, et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob. Agents Chemother. 59, 129-135 (2015
20. Sarathy, J., Dartois, V., Dick, T. & Gengenbacher, M. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57, 1648-1653 (2013
21. Bacon, J, et al. Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix. PLoS One. 9, e87329 (2014
22. Daniel, J., Sirakova, T. & Kolattukudy, P. An acyl-CoA synthetase in Mycobacterium tuberculosis involved in triacylglycerol accumulation during dormancy. PLoS One. 9, e114877 (2014
23. Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat. Rev. Microbiol. 12, 159-167 (2014
24. Lenaerts, A., Barry, C. E. 3rd & Dartois, V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol. Rev. 264, 288-307 (2015
25. Lakshminarayana, S. B, et al. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents. J. Antimicrob. Chemother. 70, 857-867 (2015